IDEAS home Printed from https://ideas.repec.org/a/eee/tefoso/v161y2020ics0040162520311598.html
   My bibliography  Save this article

Opportunities and barriers for innovation and entrepreneurship in orphan drug development

Author

Listed:
  • Belousova, Olga A.
  • Groen, Aard J.
  • Ouendag, Aniek M.

Abstract

Orphan diseases pose both a challenge to the global medical community and an opportunity for it to focus on global peace engineering and innovation. Where, any single orphan disease is rare, when taken as a whole they affect more than 250 million people throughout the world. This number by comparison is larger than the global number of cancer and AIDS patients. We add to the literature by mapping the available knowledge in the orphan drug development field and exploring the tensions at play for innovation and entrepreneurship in this field. We further add to the literature by providing a framework to review this field based on social systems theory. Our review highlights the gaps in research and proposes a path forward in understanding of and learning from the orphan drug development field.

Suggested Citation

  • Belousova, Olga A. & Groen, Aard J. & Ouendag, Aniek M., 2020. "Opportunities and barriers for innovation and entrepreneurship in orphan drug development," Technological Forecasting and Social Change, Elsevier, vol. 161(C).
    • Handle: RePEc:eee:tefoso:v:161:y:2020:i:c:s0040162520311598
    DOI: 10.1016/j.techfore.2020.120333
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0040162520311598
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.techfore.2020.120333?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Todd Sandler & Daniel G Arce M, 2002. "A conceptual framework for understanding global and transnational public goods for health," Fiscal Studies, Institute for Fiscal Studies, vol. 23(2), pages 195-222, June.
    2. Ute Stephan & Lorraine M Uhlaner & Christopher Stride, 2015. "Institutions and social entrepreneurship: The role of institutional voids, institutional support, and institutional configurations," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 46(3), pages 308-331, April.
    3. Olga Bruyaka & Hanko Zeitzmann & Isabelle Chalamon & Richard Wokutch & Pooja Thakur, 2013. "Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry," Journal of Business Ethics, Springer, vol. 117(1), pages 45-65, September.
    4. Iskrov, Georgi & Miteva-Katrandzhieva, Tsonka & Stefanov, Rumen, 2012. "Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria," Health Policy, Elsevier, vol. 108(1), pages 10-18.
    5. Moors, Ellen H.M. & Faber, Jan, 2007. "Orphan drugs: Unmet societal need for non-profitable privately supplied new products," Research Policy, Elsevier, vol. 36(3), pages 336-354, April.
    6. Clark, Kim B., 1985. "The interaction of design hierarchies and market concepts in technological evolution," Research Policy, Elsevier, vol. 14(5), pages 235-251, October.
    7. Denicolai, Stefano & Previtali, Pietro, 2020. "Precision Medicine: Implications for value chains and business models in life sciences," Technological Forecasting and Social Change, Elsevier, vol. 151(C).
    8. Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur, 2016. "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation," PharmacoEconomics, Springer, vol. 34(3), pages 285-301, March.
    9. Johanna Wiss & Lars-Ake Levin & David Andersson & Gustav Tinghög, 2017. "Prioritizing Rare Diseases: Psychological Effects Influencing Medical Decision Making," Medical Decision Making, , vol. 37(5), pages 567-576, July.
    10. Andreas Georg Scherer & Guido Palazzo, 2011. "The New Political Role of Business in a Globalized World: A Review of a New Perspective on CSR and its Implications for the Firm, Governance, and Democracy," Journal of Management Studies, Wiley Blackwell, vol. 48(4), pages 899-931, June.
    11. Merel L. Kimman & Adrienne H. Rotteveel & Marlies Wijsenbeek & Rémy Mostard & Nelleke C. Tak & Xana van Jaarsveld & Marjolein Storm & Kioa L. Wijnsma & Marielle Gelens & Nicole C. A. J. van de Kar & J, 2017. "Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire)," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 10(5), pages 629-642, October.
    12. Petra Maresova & Blanka Klimova & Kamil Kuca, 2016. "Financial and legislative aspects of drug development of orphan diseases on the European market -- a systematic review," Applied Economics, Taylor & Francis Journals, vol. 48(27), pages 2562-2570, June.
    13. Nicod, Elena & Kanavos, Panos, 2016. "Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study," Health Policy, Elsevier, vol. 120(1), pages 35-45.
    14. Paul B. Thompson, 2012. "The Agricultural Ethics of Biofuels: The Food vs. Fuel Debate," Agriculture, MDPI, vol. 2(4), pages 1-20, November.
    15. Erzurumlu, S. Sinan & Pachamanova, Dessislava, 2020. "Topic modeling and technology forecasting for assessing the commercial viability of healthcare innovations," Technological Forecasting and Social Change, Elsevier, vol. 156(C).
    16. White, Reilly & Marinakis, Yorgos & Islam, Nazrul & Walsh, Steven, 2020. "Is Bitcoin a currency, a technology-based product, or something else?," Technological Forecasting and Social Change, Elsevier, vol. 151(C).
    17. Juliane Reinecke & Shaz Ansari, 2016. "Taming Wicked Problems: The Role of Framing in the Construction of Corporate Social Responsibility," Journal of Management Studies, Wiley Blackwell, vol. 53(3), pages 299-329, May.
    18. Denis, Alain & Mergaert, Lut & Fostier, Christel & Cleemput, Irina & Simoens, Steven, 2010. "A comparative study of European rare disease and orphan drug markets," Health Policy, Elsevier, vol. 97(2-3), pages 173-179, October.
    19. ., 1998. "Technological Change," Chapters, in: Heinz D. Kurz & Neri Salvadori (ed.), The Elgar Companion to Classical Economics, volume 0, chapter 127, Edward Elgar Publishing.
    20. Douglas, Conor M.W. & Wilcox, Elizabeth & Burgess, Michael & Lynd, Larry D., 2015. "Why orphan drug coverage reimbursement decision-making needs patient and public involvement," Health Policy, Elsevier, vol. 119(5), pages 588-596.
    21. Lazonick, William & Tulum, Öner, 2011. "US biopharmaceutical finance and the sustainability of the biotech business model," Research Policy, Elsevier, vol. 40(9), pages 1170-1187.
    22. Thomas Hemphill, 2010. "Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?," Journal of Business Ethics, Springer, vol. 94(2), pages 225-242, June.
    23. Tierney, Robert & Hermina, Wahid & Walsh, Steven, 2013. "The pharmaceutical technology landscape: A new form of technology roadmapping," Technological Forecasting and Social Change, Elsevier, vol. 80(2), pages 194-211.
    24. Berlin, R.J., 2009. "Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization," American Journal of Public Health, American Public Health Association, vol. 99(9), pages 1693-1698.
    25. Salas-Vega, Sebastian & Bertling, Annika & Mossialos, Elias, 2016. "A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK," Health Policy, Elsevier, vol. 120(10), pages 1104-1114.
    26. Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur, 2016. "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation," PharmacoEconomics, Springer, vol. 34(3), pages 285-301, March.
    27. Boon, Wouter & Moors, Ellen, 2008. "Exploring emerging technologies using metaphors - A study of orphan drugs and pharmacogenomics," Social Science & Medicine, Elsevier, vol. 66(9), pages 1915-1927, May.
    28. Doug Coyle & Matthew C. Cheung & Gerald A. Evans, 2014. "Opportunity Cost of Funding Drugs for Rare Diseases," Medical Decision Making, , vol. 34(8), pages 1016-1029, November.
    29. Tortorella, Guilherme Luz & Fogliatto, Flávio Sanson & Espôsto, Kleber Francisco & Vergara, Alejandro Mac Cawley & Vassolo, Roberto & Mendoza, Diego Tlapa & Narayanamurthy, Gopalakrishnan, 2020. "Effects of contingencies on healthcare 4.0 technologies adoption and barriers in emerging economies," Technological Forecasting and Social Change, Elsevier, vol. 156(C).
    30. Gary, Robert F. & Fink, Matthias & Belousova, Olga & Marinakis, Yorgos & Tierney, Robert & Walsh, Steven T., 2020. "An introduction to the field of abundant economic thought," Technological Forecasting and Social Change, Elsevier, vol. 155(C).
    31. Boon, Wouter P.C. & Moors, Ellen H.M. & Kuhlmann, Stefan & Smits, Ruud E.H.M., 2011. "Demand articulation in emerging technologies: Intermediary user organisations as co-producers?," Research Policy, Elsevier, vol. 40(2), pages 242-252, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ravi Roshan & Krishna Chandra Balodi & Sagnika Datta & Anil Kumar & Arvind Upadhyay, 2024. "Circular economy startups and digital entrepreneurial ecosystems," Business Strategy and the Environment, Wiley Blackwell, vol. 33(5), pages 4843-4860, July.
    2. Dmitry Khanin & Robert Rosenfield & Raj V. Mahto & Cherry Singhal, 2022. "Barriers to entrepreneurship: opportunity recognition vs. opportunity pursuit," Review of Managerial Science, Springer, vol. 16(4), pages 1147-1167, May.
    3. Małgorzata Skweres-Kuchta & Iwona Czerska & Elżbieta Szaruga, 2023. "Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective," IJERPH, MDPI, vol. 20(3), pages 1-31, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Nicod, Elena & Annemans, Lieven & Bucsics, Anna & Lee, Anne & Upadhyaya, Sheela & Facey, Karen, 2019. "HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries," Health Policy, Elsevier, vol. 123(2), pages 140-151.
    2. Degtiar, Irina, 2017. "A review of international coverage and pricing strategies for personalized medicine and orphan drugs," Health Policy, Elsevier, vol. 121(12), pages 1240-1248.
    3. Marialuisa Saviano & Sergio Barile & Francesco Caputo & Mattia Lettieri & Stefania Zanda, 2019. "From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue," Sustainability, MDPI, vol. 11(5), pages 1-21, March.
    4. Douglas, Conor M.W. & Panagiotoglou, Dimitra & Dragojlovic, Nick & Lynd, Larry, 2021. "Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada," Technological Forecasting and Social Change, Elsevier, vol. 171(C).
    5. Zhang, Hao & Daim, Tugrul & Zhang, Yunqiu (Peggy), 2021. "Integrating patent analysis into technology roadmapping: A latent dirichlet allocation based technology assessment and roadmapping in the field of Blockchain," Technological Forecasting and Social Change, Elsevier, vol. 167(C).
    6. Joost W. Geenen & Svetlana V. Belitser & Rick A. Vreman & Martijn Bloois & Olaf H. Klungel & Cornelis Boersma & Anke M. Hövels, 2020. "A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 845-853, August.
    7. Kivimaa, Paula & Boon, Wouter & Hyysalo, Sampsa & Klerkx, Laurens, 2019. "Towards a typology of intermediaries in sustainability transitions: A systematic review and a research agenda," Research Policy, Elsevier, vol. 48(4), pages 1062-1075.
    8. Paula Kivimaa & Wouter Boon & Sampsa Hyysalo & Laurens Klerkx, 2017. "Towards a Typology of Intermediaries in Transitions: a Systematic Review," SPRU Working Paper Series 2017-17, SPRU - Science Policy Research Unit, University of Sussex Business School.
    9. Denicolai, Stefano & Previtali, Pietro, 2023. "Innovation strategy and digital transformation execution in healthcare: The role of the general manager," Technovation, Elsevier, vol. 121(C).
    10. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    11. Zhang, Yi & Robinson, Douglas K.R. & Porter, Alan L. & Zhu, Donghua & Zhang, Guangquan & Lu, Jie, 2016. "Technology roadmapping for competitive technical intelligence," Technological Forecasting and Social Change, Elsevier, vol. 110(C), pages 175-186.
    12. Schüßler, Elke & Lohmeyer, Nora & Ashwin, Sarah, 2022. "We can't compete on human rights: creating market-protected spaces to institutionalize the emerging logic of responsible management," LSE Research Online Documents on Economics 115506, London School of Economics and Political Science, LSE Library.
    13. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    14. Olga Bruyaka & Hanko Zeitzmann & Isabelle Chalamon & Richard Wokutch & Pooja Thakur, 2013. "Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry," Journal of Business Ethics, Springer, vol. 117(1), pages 45-65, September.
    15. Olivia Aronson & Irene Henriques, 2023. "Shared Value Creation in Equivocal CSR Environments: A Configuration Approach," Journal of Business Ethics, Springer, vol. 187(4), pages 713-732, November.
    16. Philippe Gorry & Diego Useche, 2018. "Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 305-334, National Bureau of Economic Research, Inc.
    17. Verena Girschik, 2020. "Managing Legitimacy in Business‐Driven Social Change: The Role of Relational Work," Journal of Management Studies, Wiley Blackwell, vol. 57(4), pages 775-804, June.
    18. Marinakis, Y. & Harvey, H.A. & Walsh, S.T., 2021. "The emergence of peace engineering and innovation," Technological Forecasting and Social Change, Elsevier, vol. 170(C).
    19. von Delft, Stephan & Zhao, Yang, 2021. "Business models in process industries: Emerging trends and future research," Technovation, Elsevier, vol. 105(C).
    20. Christopher Wickert, 2021. "Corporate Social Responsibility Research in the Journal of Management Studies: A Shift from a Business‐Centric to a Society‐Centric Focus," Journal of Management Studies, Wiley Blackwell, vol. 58(8), pages 1-17, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:tefoso:v:161:y:2020:i:c:s0040162520311598. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.sciencedirect.com/science/journal/00401625 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.